Join to View Full Profile
3901 Rainbow BlvdMail Stop 4033Kansas City, KS 66160
Phone+1 913-588-3600
Fax+1 913-588-3663
Dr. Shen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Xinglei Shen is a Radiation Oncology specialist based in Kansas City, KS. He completed his residency in Radiation Oncology at Sidney Kimmel Medical College at Thomas Jefferson University/TJUH following his graduation from the University of Pittsburgh School of Medicine in 2007. Presently, he serves as an Associate Professor at The University of Kansas Medical Center. Dr. Shen specializes in the treatment of genitourinary cancer. He has numerous publications in prominent medical journals about financial toxicity in radiation oncology and prostate cancer treatment. In addition, Dr. Shen has been a principal investigator and contact for several clinical trials which include research on treatments for high-risk prostate cancer and bladder cancer.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Radiation Oncology, 2008 - 2012
UPMC Medical EducationInternship, Transitional Year, 2007 - 2008
University of Pittsburgh School of MedicineClass of 2007
Certifications & Licensure
CO State Medical License 2023 - 2027
IA State Medical License 2024 - 2027
KS State Medical License 2012 - 2026
MO State Medical License 2015 - 2026
NM State Medical License 2023 - 2026
PA State Medical License 2007 - 2012
American Board of Radiology Radiation Oncology
Clinical Trials
- Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
- Ultra-hypofractionated Radiation in Prostate Cancer Start of enrollment: 2018 Mar 22
- Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer Start of enrollment: 2023 Nov 20
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Rural and Urban Differences in Prostate Cancer Recurrence.Julia B Balmaceda, Aaron J Katz, Ying Cao, Katelyn Kane, Matthew W Chen
JAMA Network Open. 2025-08-01 - Loss of MK2 Enhances Radiation-Mediated Apoptosis in Bladder Cancer.Deri Morgan, Kiersten L Berggren, Grace Millington, Hanna Smith, Colby Spiess
World Journal of Oncology. 2024-12-01 - Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTO...Zaker Rana, Sophia C Kamran, Amol C Shetty, Philip Sutera, Yang Song
European Urology Oncology. 2024-10-01
Press Mentions
Brachytherapy Reduced Death Rates in High-Risk Prostate Cancer Patients, Analysis FindsJanuary 26th, 2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
